Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
March 7, 2019
Potassium homoeostasis and pathophysiology of hyperkalaemia
Keld Per Kjeldsen, Thomas Andersen Schmidt
European Heart Journal
|
May 8, 2015
Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC
Giuseppe M C Rosano, Basil Lewis, Stefan Agewall, et al.
European Heart Journal
|
January 13, 2017
Comprehensive efforts to increase adherence to statin therapy
Alexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, et al.
European Heart Journal
|
November 11, 2017
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Alexander Niessner, Juan Tamargo, Lorenz Koller, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Juan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
November 2, 2020
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials
Heinz Drexel, Basil S Lewis, Giuseppe M C Rosano, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
May 6, 2021
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Maria Lukács Krogager, Kristian Kragholm, Jesper Qvist Thomassen, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
June 28, 2021
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy
Heinz Drexel, Stuart J Pocock, Basil S Lewis, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
February 27, 2021
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Emma Forton Magavern, Juan Carlos Kaski, Richard M Turner, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 31, 2021
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Emma F Magavern, Juan Carlos Kaski, Richard M Turner, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
March 7, 2019
Potassium homoeostasis and pathophysiology of hyperkalaemia
Keld Per Kjeldsen, Thomas Andersen Schmidt
European Heart Journal
|
May 8, 2015
Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC
Giuseppe M C Rosano, Basil Lewis, Stefan Agewall, et al.
European Heart Journal
|
January 13, 2017
Comprehensive efforts to increase adherence to statin therapy
Alexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, et al.
European Heart Journal
|
November 11, 2017
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Alexander Niessner, Juan Tamargo, Lorenz Koller, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Juan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
November 2, 2020
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials
Heinz Drexel, Basil S Lewis, Giuseppe M C Rosano, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
May 6, 2021
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Maria Lukács Krogager, Kristian Kragholm, Jesper Qvist Thomassen, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
June 28, 2021
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy
Heinz Drexel, Stuart J Pocock, Basil S Lewis, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
February 27, 2021
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Emma Forton Magavern, Juan Carlos Kaski, Richard M Turner, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 31, 2021
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Emma F Magavern, Juan Carlos Kaski, Richard M Turner, et al.
Page
of 2